Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 26, 2014

Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations

  • Etienne Cavalier EMAIL logo , Pierre Delanaye , Pierre Lukas , Agnes Carlisi , Romy Gadisseur and Jean-Claude Souberbielle

Abstract

Background: Standardization of parathyroid hormone (PTH) assays is a major issue, especially in hemodialyzed (HD) patients. Two automated third generation PTH assays (Roche Elecsys and DiaSorin Liaison) are now available. These assays are specific for the (1-84) PTH and do not cross-react with the (7-84) fragment, contrary to second generation (intact) assays. We aimed to calibrate the two methods against the WHO International PTH Standard (IS) 95/646 to see if the two assays could provide comparable results in a population of healthy subjects, HD patients and patients suffering from primary hyperparathyroidism (PHP).

Methods: We selected 79 healthy subjects and two populations of patients presenting PTH disorders: 56 HD and 27 PHP patients. We reconstituted the IS in a pool of human serum containing undetectable levels of 1-84 PTH and prepared 13 serum standards ranging from 0 to 2000 pg/mL. The standards were run on the two instruments to calibrate the assays on the IS. The different populations were run before and after restandardization.

Results: As these kits were differently calibrated, the results obtained after restandarization were significantly different. Restandardization process improved concordance between assays and, taking the analytical variability of the two kits into account, the results could be considered to be similar.

Conclusions: Restandardization of automated third generation PTH assays with the WHO 1-84 PTH Standard significantly reduces inter-method variability. Reference ranges and raw values are totally transposable from one method to the other in healthy subjects, but also in diseased patients, e.g., with HD or those suffering from PHP.


Corresponding author: Dr. Etienne Cavalier, Service de Chimie Médicale, CHU de Liège, Domaine Universitaire du Sart-Tilman, 4000, Liège, Belgium, Phone: +32 43667692, Fax: +32 43667691, E-mail:

References

1. Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2006;366:81–9.10.1016/j.cca.2005.10.010Search in Google Scholar PubMed

2. Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 2005;26:78–113.10.1210/er.2003-0024Search in Google Scholar PubMed

3. D’Amour P, Brossard JH. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005;14:330–6.10.1097/01.mnh.0000172718.49476.64Search in Google Scholar PubMed

4. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805–9.10.1093/clinchem/44.4.805Search in Google Scholar

5. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345–50.10.1038/sj.ki.5001606Search in Google Scholar PubMed

6. Hecking M, Kainz A, Bielesz B, Plischke M, Beilhack G, Hörl WH, et al. Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients. Clin Biochem 2012;45:1645–51.10.1016/j.clinbiochem.2012.08.006Search in Google Scholar PubMed

7. Cavalier E, Delanaye P, Hubert P, Krzesinski JM, Chapelle JP, Rozet E. Estimation of the stability of parathyroid hormone when stored at –80 degrees C for a long period. Clin J Am Soc Nephrol 2009;4:1988–92.10.2215/CJN.03970609Search in Google Scholar PubMed PubMed Central

8. Horowitz GL. Defining, establishing and verifying reference intervals in clinical laboratory; approved guideline, 3rd ed. Wayne, PA: CLSI, 2008.Search in Google Scholar

9. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results – a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440–5.10.1093/ndt/gfr614Search in Google Scholar PubMed PubMed Central

10. Almond A, Ellis AR, Walker SW. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012;49:63–7.10.1258/acb.2011.011094Search in Google Scholar PubMed

11. Kumar V, Barnidge DR, Chen LS, Twentyman JM, Cradic KW, Grebe SK, et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010;56:306–13.10.1373/clinchem.2009.134643Search in Google Scholar PubMed

12. Miller WG, Myers GL, Rej R. Why commutability matters. Clin Chem 2006;52:553–4.10.1373/clinchem.2005.063511Search in Google Scholar PubMed

13. Marcus R, Madvig P, Young G. Age-related changes in parathyroid hormone and parathyroid hormone action in normal humans. J Clin Endocrinol Metab 1984;58:223–30.10.1210/jcem-58-2-223Search in Google Scholar PubMed

Received: 2013-11-28
Accepted: 2014-2-19
Published Online: 2014-3-26
Published in Print: 2014-8-1

©2014 by Walter de Gruyter Berlin/Boston

Downloaded on 28.4.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2013-1027/html
Scroll to top button